Hence, unlike CAR T cells that require autologous T cells, therapeutic CD19-CAR-NK cells could be generated as an off-the-shelf product from healthy donors and hold the potential of also attacking CD19-negative leukemia cells through natural cytotoxicity mechanisms [43]. The gene discussed is CD19; the disease is leukemia.